Pfizer-BioNTech seeks approval to use vaccine on children aged 5 to 11 years
Nov 12, 2021
Canada’s review of Pfizer-BioNTech’s COVID-19 vaccine for children between the ages of 5 to 11 should be completed within the next “one to two weeks,” Health Canada’s chief medical adviser says.
“As with all of the COVID-19 submissions, we’re doing it on a priority basis and we have a dedicated team that’s looking at that data and that data is not just the clinical data, but as well the formulation,” Dr. Supriya Sharma told a Public Health Agency of Canada briefing in Ottawa today. “And we look at that in the Canadian context for the … possible use in children.”
Three weeks ago, Pfizer-BioNTech became the first company to seek Health Canada’s approval for a pediatric COVID-19 vaccine. Other companies, including Moderna, are working on children’s formulations.
While children aged 12 and older are already approved for the adult formulation, the pediatric formulation would be given in two smaller doses — 10 mcg (micrograms), instead of the 30 mcg used for those over the age of 12.
Read more: https://www.cbc.ca/news/politics/pfizer-vaccine-children-1.6247035